Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings
We read with interest the recent publication by Dietz et al: “Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy” and would like to present additional data regarding salvage hepatitis C virus (HCV) treatment in this difficult-to-cure patient population.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Michelle T. Martin, Sonalie Patel, Laura Kulik, Christine Chan Tags: Letter to the Editor Source Type: research